ADA: Glucose Self-Monitoring Often Lacks Benefit in T2DM

Share this content:
ADA: Glucose Self-Monitoring Often Lacks Benefit in T2DM
ADA: Glucose Self-Monitoring Often Lacks Benefit in T2DM

MONDAY, June 12, 2017 (HealthDay News) -- For most patients with non-insulin-treated type 2 diabetes, routine self-monitoring of blood glucose does not significantly improve hemoglobin A1c levels or health-related quality of life, according to a study published online June 10 in JAMA Internal Medicine. The research was published to coincide with the annual meeting of the American Diabetes Association, held from June 9 to 13 in San Diego.

Laura Young, M.D., Ph.D., from the University of North Carolina School of Medicine at Chapel Hill, and colleagues randomly assigned 450 patients with type 2 diabetes who weren't taking insulin to monitor their blood glucose levels once a day with a typical glucometer, once a day with a monitor that gave them a feedback message, or to not monitor blood glucose levels at all. The participants in the study were from 15 primary care practices in North Carolina. Their average age was 61, and they'd had diabetes for an average of eight years.

After a year, the researchers found no differences between the groups in how well their blood glucose levels were controlled or in their quality of life. The team also found no notable differences in hypoglycemia frequency, health care utilization, or insulin initiation.

"Patients and clinicians should consider the specifics of each clinical situation as they decide whether to test or not to test," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Abstract/Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths